Home Stock

Stock Research: AstraZeneca

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

AstraZeneca

LSE:AZN GB0009895292
52
  • Value
    34
  • Growth
    84
  • Safety
    Safety
    17
  • Combined
    34
  • Sentiment
    79
  • 360° View
    360° View
    52
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. It operates in oncology, rare diseases, and biopharmaceuticals. In the last fiscal year, the company had a market cap of $216,842 million, profits of $44,415 million, revenue of $54,073 million, and 94,300 employees.

more

ANALYSIS: With an Obermatt 360° View of 52 (better than 52% compared with alternatives), overall professional sentiment and financial characteristics for the stock AstraZeneca are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for AstraZeneca. The consolidated Growth Rank has a good rank of 84, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 84% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 79, which means that professional investors are more optimistic about the stock than for 79% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 34, which means that the share price of AstraZeneca is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 66% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 17, which means that the company has a financing structure that is riskier than those of 83% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Safety
Weakest Rank Profit Growth
Country United Kingdom
Industry Pharmaceuticals
Size XX-Large
Website astrazeneca.com
Index
FTSE All Shares
FTSE 100
FTSE 350
NASDAQ
OMX 30
Renewables Users
AstraZeneca stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
34 46 43 60
Growth
84 48 73 81
Safety
Safety
17 7 10 47
Sentiment
79 45 88 90
360° View
360° View
52 23 53 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 69 78 67
Opinions Change
50 19 52 52
Pro Holdings
n/a 87 92 80
Market Pulse
32 35 35 59
Sentiment
79 45 88 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
34 46 43 60
Growth
84 48 73 81
Safety Safety
17 7 10 47
Combined
34 15 28 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
39 26 28 44
Price vs. Earnings (P/E)
28 51 51 58
Price vs. Book (P/B)
28 18 15 34
Dividend Yield
63 71 74 70
Value
34 46 43 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
62 55 67 76
Profit Growth
96 42 60 74
Capital Growth
60 37 64 53
Stock Returns
48 67 42 68
Growth
84 48 73 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
27 20 20 9
Refinancing
23 6 7 96
Liquidity
53 54 44 32
Safety Safety
17 7 10 47

Similar Stocks

Discover high‑ranked alternatives to AstraZeneca and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Metlen Energy & Metals

LSE:MTLN
Country: United Kingdom
Industry: Industrial Conglomerates
Size: Large
Full Stock Analysis

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews